Novel and specific respiratory syncytial virus inhibitors that target virus fusion.
Departments of Bioorganic/Enzymology, Wyeth-Lederle Vaccines and Pediatrics, Medicinal Chemistry, and Infectious Diseases, Wyeth-Ayerst Research, Pearl River, New York 10965, USA.
W D
WD
Ding
B
B
Mitsner
G
G
Krishnamurthy
A
A
Aulabaugh
C D
CD
Hess
J
J
Zaccardi
M
M
Cutler
B
B
Feld
A
A
Gazumyan
Y
Y
Raifeld
A
A
Nikitenko
S A
SA
Lang
Y
Y
Gluzman
B
B
O'Hara
G A
GA
Ellestad
D000818:Animals; D002460:Cell Line; D002522:Chlorocebus aethiops; D003587:Cytomegalovirus / Q000187:drug effects; D015707:HN Protein; D006801:Humans; D011485:Protein Binding; D018113:Respiratory Syncytial Virus, Human / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D018139:Simplexvirus / Q000187:drug effects; D013050:Spectrometry, Fluorescence; D013329:Structure-Activity Relationship; D014227:Triazines / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D014461:Ultracentrifugation; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins / Q000378:metabolism*; D014764:Viral Proteins / Q000378:metabolism*
D015707:HN Protein; D014227:Triazines; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; D014764:Viral Proteins; C116204:attachment protein G